CARGO Therapeutics Competitors and Similar CompaniesClear all

CARGO Therapeutics's competitors and similar companies include AsclepiX Therapeutics, Medicenna Therapeutics, Nkarta Therapeutics and Lyell.

	CARGO Therapeutics CARGO Therapeutics (formerly known as Syncopation Life Sciences) is a company that develops a platform for cancer treatment.	AsclepiX Therapeutics AsclepiX Therapeutics is a biopharmaceutical company which focuses on therapies based on a peptide platform.	Medicenna Therapeutics Medicenna Therapeutics is an immunotherapy company focused on oncology.	Nkarta Therapeutics Nkarta Therapeutics is a biopharmaceutical company developing engineered natural killer (NK) cell therapies for the treatment of cancer.	Lyell Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
Founding Date	Founding Date 2019	Founding Date 2011	Founding Date 2012	Founding Date 2015	Founding Date 2018
Type	Type Public	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech oncology platform therapy	Tags Healthcare biotech oncology platform therapy	Tags Healthcare biotech oncology platform therapy	Tags Healthcare biotech oncology platform therapy	Tags Healthcare biotech oncology platform therapy
Locations	Locations San Mateo, US HQ	Locations Baltimore, US HQ Jersey City, US	Locations HQ	Locations South San Francisco, US HQ	Locations South San Francisco, US HQ Bothell, US Seattle, US
Employees	Employees 74	Employees 827% decrease	Employees 7	Employees 1594% decrease	Employees 188
Valuation ($)	Valuation ($) 1 b	Valuation ($) N/A	Valuation ($) 122.2 m	Valuation ($) 240.6 m	Valuation ($) 243.3 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $130k (FY, 2023)
Net income	Net income ($98.1m) (FY, 2023)	Net income N/A	Net income ($25.5m) (FY, 2024)	Net income ($117.5m) (FY, 2023)	Net income ($234.6m) (FY, 2023)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 40m	Total funding raised $ 7.5m	Total funding raised $ 125m	Total funding raised N/A